Clinical Report: Euretina 2025 Opens With Record Attendance
Overview
The 25th annual Euretina Congress in Paris achieved record attendance with over 10,000 participants. Key discussions included the integration of artificial intelligence in retinal care, particularly for age-related macular degeneration, emphasizing its practical applications in clinical settings.
Background
The Euretina Congress serves as a pivotal platform for advancements in retinal research and clinical practice. The increasing participation reflects the growing interest and need for collaboration in the field of retina specialists. The congress highlights the importance of innovative technologies, such as AI, in enhancing patient care and treatment outcomes.
Data Highlights
No numerical data or trial results were reported in the article, but discussions highlighted trends in AI applications in retinal care.
Key Findings
- Record attendance of over 10,000 participants at the Euretina Congress.
- Keynote by Ursula Schmidt-Erfurth emphasized AI's role in managing age-related macular degeneration.
- Prithvi Ramtohul received the Professor Ramin Tadayoni Award for his research on neuronal excitability, highlighting the importance of innovative research in retinal health.
- Josef Huemer and Kanmin Xue were recognized for their innovative studies using AI in retinal research, showcasing the integration of technology in clinical practice.
- Honorary diplomas were awarded for contributions to the FEBOS-Retina certification program, underscoring the commitment to professional development in the field.
Clinical Implications
The integration of AI in retinal care signifies a shift towards more personalized and efficient treatment strategies. Clinicians should stay informed about these advancements and consider how to incorporate AI tools into their practice to enhance patient outcomes.
Conclusion
The Euretina Congress not only showcases the latest research and innovations in retinal care but also emphasizes the collaborative spirit of the retina community in advancing patient care.
References
- retinal physician, EYP-1901 Shows Durable, Sustained Efficacy in VERONA, 2025 -- EYP-1901 Shows Durable, Sustained Efficacy in VERONA
- Eyecare Business, DaTE 2025 Announces Exhibitor Lineup, 2025 -- DaTE 2025 Announces Exhibitor Lineup
- Eyecare Business, Show Time, 2021 -- Show Time
- eyecare business, Ready, Set, Orlando, 2025 -- Ready, Set, Orlando
- Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel, Eye, 2025 -- Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel
- Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials - PubMed, 2025 -- Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - ScienceDirect, 2025 -- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
- Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel | Eye
- Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials - PubMed
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.